CMS proposes NTAP reimbursement for EBR's WiSE CRT at max 65% rate

EBR Systems, Inc.

CMS proposed NTAP for WiSE CRT System for FY 2026 at maximum add-on payment of 65% of device cost.
NTAP is in addition to standard MS-DRG payment, intended to fully cover device cost.
NTAP effective from 1 Oct 2025 for three years, subject to final CMS rule expected August 2025.
EBR plans to apply for Transitional Pass-through reimbursement for outpatients shortly.
FDA approval of WiSE CRT also announced; both milestones advance US commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.